Sudeep Pharma Board of Directors

Get the latest insights into the leadership at Sudeep Pharma. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Sujit Jaysukh Bhayani Managing & Wholetime Director
Ms. Shanil Sujit Bhayani Whole Time Director
Mr. Ajay Shrirang Kandelkar Whole Time Director
Mr. Raghunandan Sathyanarayan Rao Independent Director
Ms. Reshma Suresh Patel Independent Director
Mr. Samaresh Parida Independent Director
Mr. Sujit Gulati Independent Director

Sudeep Pharma Share price

SUDEEPPHRM

669.2

11.95 (-1.75%)
NSE
BSE
Last updated on 4 Dec, 2025 | 15:59 IST
BUYSELL
Today's High

714.70

Today's Low

658.20

52 Week Low

658.20

52 Week High

795.00

The current prices are delayed, login to your account for live prices

Sudeep Pharma FAQs

The board at Sudeep Pharma consists of experienced professionals, including Mr. Sujit Jaysukh Bhayani , Ms. Shanil Sujit Bhayani , and others, overseeing the company’s strategic and corporate governance.

Directors at Sudeep Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Sujit Jaysukh Bhayani is the current chairman at Sudeep Pharma.

Executive directors at Sudeep Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Sudeep Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Sudeep Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.